{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:24:46Z","timestamp":1782332686692,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.maturitas.2018.11.017","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T11:55:51Z","timestamp":1543406151000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety"],"prefix":"10.1016","volume":"121","author":[{"given":"Violante","family":"Di Donato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Carlo","family":"Schiavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"D\u2019oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-5815","authenticated-orcid":false,"given":"Evangelos","family":"Kontopantelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-0079","authenticated-orcid":false,"given":"Tommaso","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-9583","authenticated-orcid":false,"given":"Ludovico","family":"Muzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Benedetti Panici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"November 11","key":"10.1016\/j.maturitas.2018.11.017_bib0005","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/GME.0000000000000464","article-title":"Prevalence of postmen- opausal symptoms in North America and Europe","volume":"22","author":"Minkin","year":"2015","journal-title":"Menopause"},{"issue":"January 1","key":"10.1016\/j.maturitas.2018.11.017_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin. Proc."},{"issue":"Febuary 2","key":"10.1016\/j.maturitas.2018.11.017_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/GME.0b013e318295236f","article-title":"Clarifying Vaginal Atrophy\u2019s Impact on Sex and Re- lationships(CLOSER) survey: emotional and physical impact of vaginal discomfort on North American post- menopausal women and their partners","volume":"21","author":"Simon","year":"2014","journal-title":"Menopause"},{"issue":"August 4","key":"10.1016\/j.maturitas.2018.11.017_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.maturitas.2013.05.003","article-title":"Gir- aldi A. The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe","volume":"75","author":"Nappi","year":"2013","journal-title":"Maturitas"},{"issue":"September 9","key":"10.1016\/j.maturitas.2018.11.017_bib0025","first-page":"888","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause"},{"issue":"Fabuary (1)","key":"10.1016\/j.maturitas.2018.11.017_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal health: insights, views & attitudes (VIVA)\u2014results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"issue":"January (3)","key":"10.1016\/j.maturitas.2018.11.017_bib0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/13697137.2012.756466","article-title":"Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview","volume":"16","author":"Sinha","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2018.11.017_bib0040","series-title":"Senshio (60 Mg Film-coated Tablets). Ospemifene Summary of Product Characteristics","year":"2015"},{"key":"10.1016\/j.maturitas.2018.11.017_bib0045","series-title":"Osphena [(ospemifene) Tablets, for Oral Use]. Prescribing Information","year":"2013"},{"issue":"September-October (5)","key":"10.1016\/j.maturitas.2018.11.017_bib0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2018.11.017_bib0055","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvo- vaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.maturitas.2018.11.017_bib0060","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause: J. North Am. Menopause Soc."},{"key":"10.1016\/j.maturitas.2018.11.017_bib0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climateric"},{"issue":"6","key":"10.1016\/j.maturitas.2018.11.017_bib0070","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2014","journal-title":"Menopause: J. North Am. Menopause Soc."},{"key":"10.1016\/j.maturitas.2018.11.017_bib0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","article-title":"Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment ovaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial","volume":"78","author":"Portman","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2018.11.017_bib0080","unstructured":"Higgins JPT, Green S,eds. Cochrane handbook for systematic reviews of interventions, v.5.1. New Jersey: Wiley-Blackwell; updated March 2011. Cochrane Collaboration Web site. Available at: http:\/\/www.cochrane-handbook.org."},{"issue":"January 1","key":"10.1016\/j.maturitas.2018.11.017_bib0085","first-page":"14","article-title":"Overall safety of Ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. Simon JA, Altomare C, Cort S, Jiang W, pinkerton JV","volume":"27","year":"2018","journal-title":"J. Womens Health (Larchmt)"},{"issue":"5","key":"10.1016\/j.maturitas.2018.11.017_bib0090","first-page":"605","article-title":"Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast","volume":"25","author":"Soe","year":"2013","journal-title":"Int. J. Womens Health"},{"issue":"5","key":"10.1016\/j.maturitas.2018.11.017_bib0095","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0034-1367032","article-title":"Effects of ospemifene on breast tissue morphology and proliferation: a comparative study versus other selective estrogen receptor modulators in ovariectomized rats","volume":"46","author":"Kangas","year":"2014","journal-title":"Horm. Metab. Res."},{"issue":"Jul. (7)","key":"10.1016\/j.maturitas.2018.11.017_bib0100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/GME.0000000000000624","article-title":"Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo","volume":"23","author":"Eigeliene","year":"2016","journal-title":"Menopause."},{"issue":"10","key":"10.1016\/j.maturitas.2018.11.017_bib0105","article-title":"Ospemifene\u2019s effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data","volume":"24","author":"Archer","year":"2017","journal-title":"Menopause: J. North Am. Menopause Soc."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218307436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218307436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:14:35Z","timestamp":1759914875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512218307436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":21,"alternative-id":["S0378512218307436"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2018.11.017","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2018.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}